Llwytho...
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an urgent unmet need to improve the therapeutic options available. Novel immunothera...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Med Oncol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299311/ https://ncbi.nlm.nih.gov/pubmed/30574212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918816281 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|